|
|
||||||||
1From the Department of Ophthalmology, Juntendo University School of Medicine, Tokyo, Japan; and the 2National Institute of Ophthalmology, Hanoi, Vietnam.
| Abstract |
|---|
|
|
|---|
METHODS. Nineteen unrelated families, including 35 patients and 38 unaffected relatives were examined clinically. Blood samples were collected. Fifty normal Vietnamese individuals served as control subjects. Genomic DNA was extracted from leukocytes. Analysis of the CHST6 gene was performed with polymerase chain reaction and direct sequencing. Corneal buttons were studied histopathologically.
RESULTS. A slit lamp examination revealed clinical features of MCD with gray-white opacities and stromal haze between. On histopathology, corneal sections showed positive staining with colloidal iron. Sequencing of the CHST6 gene revealed six homozygous and three compound heterozygous mutations. The homozygous mutations, including L59P, V66L, R211Q, W232X, Y268C, and 1067-1068ins(GGCCGTG) were detected, respectively, in two, one, eight, one, one, and two families. Compound heterozygous mutations R211Q/Q82X, S51L/Y268C, and Y268C/1067-1068ins(GGCCGTG) were identified, each in one family. A single heterozygous change at codon 76 (GTG
ATG) was detected in family L, resulting in a valine-to-methionine substitution (V76M). None of these mutations was detected in the control group.
CONCLUSIONS. Mutations identified in the CHST6 gene cosegregated with the disease phenotype in all but one family studied and thus caused MCD. Among these, the R211Q detected in 9 of 19 families may be the most common mutation in Vietnamese. These data also indicate that significant allelic heterogeneity exists for MCD.
Although clinically indistinguishable, MCD has been subdivided into three immunophenotypes (MCD types I, IA, and II) based on measurement of the serum level of sulfated keratan sulfate (KS) and an immunohistochemical evaluation of the corneal tissue.3 4 Histopathologically, MCD is characterized by accumulation of glycosaminoglycans in the epithelium, Bowmans layer, stroma, Descemets membrane, and endothelium, as well as within stromal keratocytes.5 6
A gene responsible for MCD types I and II has been linked to chromosome 16 (q22).7 8 9 Recently, mutations in a new carbohydrate sulfotransferase gene (CHST6) encoding corneal glucosamine N-acetyl-6-sulfotransferase (C-GlcNac-6-ST) have been identified as the cause of MCD.10 In the subjects with MCD type I or IA, numerous missense mutations of CHST6 gene were found to be responsible (Bao W, Smith CF, Al-Rajhi A, Chandler JW, Karcioglu ZA, Akama TO, Fukuda MN, Klintworth GK, ARVO Abstract 2609, 2001).10 11 12 For MCD type II, deletion and/or rearrangements in the upstream region and, recently, a missense mutation were described.10 12
In this study, we analyzed the CHST6 gene for mutations in 19 Vietnamese families with clinical diagnosis of MCD, including 2 families affected by MCD in two consecutive generations.
| Materials and Methods |
|---|
|
|
|---|
The study was performed according to the tenets of the World Medical Associations Declaration of Helsinki regarding research involving human subjects. Informed signed consent was obtained from the affected and unaffected family members and from control subjects. This was a joint research project between the NIO, Hanoi, Vietnam, and Juntendo University, Tokyo, Japan, approved by the Ministry of Health of Vietnam (Agreement 10887 YT/QT) and the Ethics Committee of Juntendo University (No. 109).
Mutation Analysis
Genomic DNA was extracted from blood leukocytes by standard procedures.13 The coding region of the CHST6 gene was amplified by polymerase chain reaction (PCR) using each pair of primers and PCR conditions by Akama et al.10 except for the middle coding region, where primers 743F (5'-GCAGACCTTCCTCCTCCTCT-3') and 1578R (5'-TGAGACTGAGCCCAGTGAAG-3') were used. The upstream regions of the CHST6 gene (regions A and B) were analyzed for deletion and replacement mutation by PCR.10 The promoter region (326 bp upstream from start codon) was amplified with a pair of primers: forward/reverse (GGTAATGTGGGTAGGTAGAAC/AGAAAGAGGAGGAGGAAGGTC). For direct sequencing, PCR products were purified with a kit (High Pure PCR Purification; Roche Diagnostics GmbH, Mannheim, Germany)14 15 and then the terminator reaction was performed with a DNA sequencing kit (Big Dye Terminator Cycle Sequencing, Ready Reaction; Applied Biosystems, Foster City, CA). Sequencing was performed in an automated DNA Sequencer (model 377; Applied Biosystems) in both sense and antisense strands. Nucleotide sequences were compared with the published cDNA sequence of the CHST6 gene (GenBank accession number AF219990; http://www.ncbi.nlm.nih.gov/Genbank; provided in the public domain by the National Center for Biotechnology Information, Bethesda, MD).
Pathologic Study
Corneal buttons obtained from 32- and 45-year-old patients at keratoplasty were fixed in 10% buffered formaldehyde solution for routine paraffin wax embedding and light microscopy. Cross sections of each button were prepared and stained with colloidal iron. Unfortunately, we could not perform an assay of KS in serum.
| Results |
|---|
|
|
|---|
|
Sequencing of the CHST6 gene within the coding region revealed nine different mutations in 19 unrelated families (Table 1) . Of these, six changes were homozygous and were detected in most of the families. The nucleotide changes: T868C at codon 59 (CTC
CCC), G888C at codon 66 (GTC
CTC), G1324A at codon 211 (CGG
CAG), G1388A at codon 232 (TGG
TGA), and A1495G at codon 268 (TAC
TGC) were identified, resulting, respectively, in a leucine-to-proline (L59P), a valine-to-leucine (V66L), an arginine-to-glutamine (R211Q), a tryptophan-to-stop (W232X), and a tyrosine-to-cysteine (Y268C) substitution
(Figs. 2a
2B
2C
2D
2E) . In two families, an insertion of 7 bp between nucleotides 1067 and 1068nt 1067-1068ins(GGCCGTG)was identified, resulting in a frameshift after codon 125 (frameshift after 125V;
Fig. 2F ).
|
|
TTG) and A1495C at codon 268 (TAC
TGC) were identified, predicting an amino acid change of serine to leucine (S51L) and tyrosine to cysteine (Y268C), respectively
(Figs. 3A
3B) . In family N, a heterozygous change, C936T at codon 82 (CAG
TAG), replacing a glutamine with a stop codon was detected, along with a G1324A change at codon 211 (CGG
CAG, R211Q; Figs. 3C 3D ). In family V2, heterozygous changes, A1495G, at codon 268 (TAC
TGC, Y268C) and nt1067-1068ins(GGCCGTG) were identified
(Figs. 3E
3F) . In family L, a single heterozygous change, G918A, at codon 76 (GTG
ATG) was detected, resulting in a valine-to-methionine substitution (V76M;
Fig. 3G ).
|
| Discussion |
|---|
|
|
|---|
Sequencing analysis of the CHST6 coding region revealed nine distinct alterations of the nucleotide sequence in the patients from 19 families. Of these, six changes, T868C, G888C, G1324A, A1495G, G1388A, and a 7-bp insertion between nucleotides 1067 and 1068, were identified as homozygous. The nucleotide change results in missense mutations with modification of amino acids in the protein product (L59P, V66L, R211Q, and Y268C), causes an early stop codon (W232X), and affects the translated protein (frameshift after 125V). Two other changes: heterozygous C844T and C936T were found in association with the changes A1495G, G1324A, and 1067-1068ins(GGCCGTG), resulting in a compound of different mutations on each allele: S51L/Y268C (family T), R211Q/Q82X (family N), and Y268C frameshift after 125V (family V2). These compound heterozygous mutations could also account for MCD as a recessive disorder. A single heterozygous alteration G918A identified in family L could not be regarded as a cause of the MCD phenotype; further investigation upstream of the CHST6 gene (other than regions A and B) for deletion or replacement mutation or analysis of the other genes, such as CHST4 and CHST5, would be necessary. None of these nucleotide alterations was detected in the 50 control subjects of Vietnamese origin, indicating that these were true disease-causing mutations. Six homozygous and three compound heterozygous mutations cosegregated with the disease phenotype in each pedigree and thus caused MCD in our patients.
The molecular basis of the manifestation of MCD has not yet been elucidated. It has been shown that the decrease in C-GlcNac-6-ST activity in the cornea of patients with MCD may result in the formation of poorly or nonsulfated KS and cause corneal opacity.18 The mutations of the CHST6 gene found in our patients infer an essential role of C-GlcNac-6-ST, the CHST6 protein product, in the production of normally functioning KS. Among various mutations found in Vietnamese patients, R211Q was detected at a relatively high frequency (eight families were homozygous and one family was heterozygous for the mutation).
Although the immunophenotypes of our patients could not be subdivided, most genetic alterations identified herein were missense mutations. Those were described in patients with MCD type I or IA. In our patients, all mutations were detected within the middle coding region amplified with primers 743F and 1578R. Therefore, using this pair of primers may facilitate mutation screening of patients with MCD. The mutations identified in Vietnamese are completely different from the ones reported previously in Asians (Japanese)10 or whites (British and Icelandic).11 12 Together with previous reports,10 11 12 our data indicate that significant allelic heterogeneity exists for MCD.
| Acknowledgements |
|---|
| Footnotes |
|---|
Submitted for publication January 13, 2003; revised February 27, 2003; accepted March 6, 2003.
Disclosure: N.T. Ha, None; H.M. Chau, None; L.X. Cung, None; T.K. Thanh, None; K. Fujiki, None; A. Murakami, None; Y. Hiratsuka, None; A. Kanai, None
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be marked "advertisement" in accordance with 18 U.S.C.
1734 solely to indicate this fact.
Corresponding author: Nguyen Thanh Ha, Department of Ophthalmology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan; hant02{at}yahoo.com.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
A. J. Aldave and B. Sonmez Elucidating the Molecular Genetic Basis of the Corneal Dystrophies: Are We There Yet? Arch Ophthalmol, February 1, 2007; 125(2): 177 - 186. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Hayashida, T. O. Akama, N. Beecher, P. Lewis, R. D. Young, K. M. Meek, B. Kerr, C. E. Hughes, B. Caterson, A. Tanigami, et al. Matrix morphogenesis in cornea is mediated by the modification of keratan sulfate by GlcNAc 6-O-sulfotransferase PNAS, September 5, 2006; 103(36): 13333 - 13338. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |